Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530692 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL18530688 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL6698774 | 0.82 | NPC1 (0.70) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL8568986 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL851358 | 0.79 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL29540343 | 0.79 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL27347353 | 0.79 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL5778496 | 0.79 | NPC1 (0.58) | SMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL12522917 | 0.79 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL12043743 | 0.78 | GRN (0.67) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445677-B2 | Substituted pyrimidyl guanidine derivatives having anticancer activity | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | ABCG2, NQO2, TOP1 | SMN1; SMN2 4511/4885ALDH1A1 1121/4885HPGD 1106/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | SMN1; SMN2 248/4885ALDH1A1 1558/4885HPGD 864/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | SMN1; SMN2 248/4885ALDH1A1 1558/4885HPGD 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.